Does aspirin use prevent acute coronary syndrome in patients with pneumonia: multicenter prospective randomized trial

Basit Öğe Kaydı
dc.authorid0000-0002-0891-0020
dc.authorscopusid48361867800
dc.authorscopusid37116845700
dc.authorscopusid7101694776
dc.authorscopusid7007162316
dc.authorscopusid8245053000
dc.authorscopusid14628108500
dc.authorscopusid55540597200
dc.authorwosidGunay, Ersin/B-4324-2013
dc.authorwosidElitok, Ali/AAE-5404-2020
dc.authorwosidYAZICI, MEHMET/AAP-9375-2020
dc.contributor.authorÖz, Fahrettin
dc.contributor.authorGül, Sule
dc.contributor.authorKaya, Mehmet G.
dc.contributor.authorYazıcı, Mehmet
dc.contributor.authorBulut, İsmet
dc.contributor.authorElitok, Ali
dc.contributor.authorOflaz, Hüseyin
dc.contributor.authorAkkoyun, Cayan D.
dc.date.accessioned2022-05-11T14:40:07Z
dc.date.available2022-05-11T14:40:07Z
dc.date.issued2013
dc.departmentFakülteler, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Kardiyoloji Ana Bilim Dalı
dc.description.abstractObjectives The aim of this study was to test the hypothesis that aspirin would reduce the risk for acute coronary syndromes (ACSs) in patients with pneumonia. Backgrounds Pooled data suggest that pneumonia may trigger an ACS as a result of inflammatory reactions and the prothrombotic changes in patients with pneumonia. Hypothetically considering its antiaggregating and anti-inflammatory effects, aspirin might also be beneficial for the primary prevention of ACS in patients with pneumonia. Methods One hundred and eighty-five patients with pneumonia who had more than one risk factor for cardiovascular disease were randomized to an aspirin group (n = 91) or a control group (n = 94). The patients in the aspirin group received 300 mg of aspirin daily for 1 month. ECGs were recorded on admission and 48 h and 30 days after admission to assess silent ischemia. The level of high-sensitivity cardiac troponin T was measured on admission and 48 h after admission. The primary endpoint was the development of ACS within 1 month. The secondary endpoints included cardiovascular death and death from any cause within 1 month. Results The chi(2)-test showed that the rates of ACS at 1 month were 1.1% (n = 1) in the aspirin group and 10.6% (n = 10) in the control group (relative risk, 0.103; 95% confidence interval 0.005-0.746; P = 0.015). Aspirin therapy was associated with a 9% absolute reduction in the risk for ACS. There was no significant decrease in the risk of death from any cause (P = 0.151), but the aspirin group had a decreased risk of cardiovascular death (risk reduction: 0.04, P = 0.044). Conclusion This randomized open-label study shows that acetyl salicylic acid is beneficial in the reduction of ACS and cardiovascular mortality among patients with pneumonia. Coron Artery Dis 24:231-237 (c) 2013 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins. Coronary Artery Disease 2013, 24:231-237
dc.identifier.doi10.1097/MCA.0b013e32835d7610
dc.identifier.endpage237
dc.identifier.issn0954-6928
dc.identifier.issn1473-5830
dc.identifier.issue3en_US
dc.identifier.pmid23283029
dc.identifier.scopus2-s2.0-84876405926
dc.identifier.scopusqualityQ3
dc.identifier.startpage231
dc.identifier.urihttps://doi.org/10.1097/MCA.0b013e32835d7610
dc.identifier.urihttps://hdl.handle.net/20.500.11776/8870
dc.identifier.volume24
dc.identifier.wosWOS:000317395000009
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorAkkoyun, Cayan D.
dc.language.isoen
dc.publisherLippincott Williams & Wilkins
dc.relation.ispartofCoronary Artery Disease
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectacetyl salicylic acid
dc.subjectacute coronary syndrome
dc.subjectinfection pneumonia
dc.subjectprimary prevention
dc.subjectEndothelial Dysfunction
dc.subjectCardiovascular-Disease
dc.subjectPneumococcal Pneumonia
dc.subjectMyocardial-Infarction
dc.subjectPlatelet Activation
dc.subjectHeart-Disease
dc.subjectUric-Acid
dc.subjectRisk
dc.subjectInfection
dc.subjectInflammation
dc.titleDoes aspirin use prevent acute coronary syndrome in patients with pneumonia: multicenter prospective randomized trial
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
8870.pdf
Boyut:
389.85 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
Tıp Fakültesi Koleksiyonu